To read the full story, subscribe or sign in.

Boundless Bio closes $100M series C round to target extrachromosomal-DNA-driven cancers

May 16, 2023

Boundless Bio Inc. raised $100 million in a series C round to continue its highly distinctive approach to cancer therapy, which is based on disrupting the functioning of highly amplified oncogenic extrachromosomal DNA fragments.

BioWorld Financings Cancer Series C

Today's news in brief

BioWorld

BioWorld briefs for Nov. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 17, 2025.

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...